Latest Rifampicin Stories
Two research studies suggest that a new automated DNA test for tuberculosis (Xpert MTB/RIF), which can detect TB within 2 hours and has been endorsed by the World Health Organization, can significantly increase TB detection rate compared to other tests, particularly in HIV positive patients who have a high risk of being infected with TB, including multidrug resistant TB.
Johns Hopkins and South African scientists have further compelling evidence that new, simpler and shorter treatments with antibiotic drugs could dramatically help prevent tens of millions of people worldwide already infected with the bacterium responsible for tuberculosis, and especially those co-infected with HIV, from developing full-blown TB.
PARIS, June 29, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it entered into a research collaboration with Weill Cornell Medical College to develop new anti-infectives that aim to shorten the course of treatment of tuberculosis (TB) and provide effective therapies against drug-susceptible and drug-resistant strains of TB. (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) Under the terms of the collaboration, Sanofi will provide 80,000 chemical...
In patients with newly-diagnosed tuberculosis (TB), use of a combined four-drug, fixed-dose regimen was found to have comparable outcomes to drugs administered separately, according to a new study.
Scientists have discovered a new way to attack dangerous pathogens, marking a hopeful next step in the ever-escalating battle between man and microbe.
SUNNYVALE, Calif., Sept.
Scientists have identified a strain of antibiotic-resistant tuberculosis that thrives in the presence of rifampin, a front-line drug in the treatment of tuberculosis.
International guidelines for treating tuberculosis are due for specific improvements, according to two research papers published this week in the open access journal PLoS Medicine.
Test for Mycobacterium tuberculosis (TB) Expected to Highlight Broad On-Demand CE IVD Test Menu at Booth #611 SUNNYVALE, Calif., April 28 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced speaker and program highlights for its symposium, "Patient Management in the Era of Rapid Diagnostics," which the company will host at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place in Finland next month.
Unique GeneXpert(R) System Capabilities Enable Powerful New TB Diagnostic Tool SUNNYVALE, Calif., April 27 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the release of Xpert(R) MTB/RIF as a CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices.
Mycobacterium tuberculosis (MTB) is a pathogenic bacterial species in the genus Mycobacterium and the causative agent of most cases of tuberculosis. Robert Koch first discovered it in 1882 and that it had an unusual, waxy coating on the cell surface which makes them impossible to Gram stain. M. tuberculosis is highly aerobic and requires high levels of oxygen. It generally infects the respiratory system of mammals. Tuberculin skin test, acid-fast stain, and chest radiographs are the most...